Novel retinoblastoma treatment avoids chemotherapy: The effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LHBETATAG retinoblastoma tumors

Samuel K. Houston, Yolanda Piña, Timothy G. Murray, Hinda Boutrid, Colleen Cebulla, Amy C. Schefler, Wei Shi, Magda Celdran, William Feuer, Jaime Merchan, Ted J. Lampidis

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Purpose: The purpose of this study was to evaluate the effect of optimally timed combination treatment with angiogenic and glycolytic inhibitors on tumor burden, hypoxia, and angiogenesis in advanced retinoblastoma tumors. Methods: L HBETATAG mice (n = 30) were evaluated. Mice were divided into 5 groups (n = 6) and received injections at 16 weeks of age (advanced tumors) with a) saline, b) anecortave acetate (AA), c) 2-deoxyglucose (2-DG), d) AA + 2-DG (1 day post-AA treatment), or e) AA + 2-DG (1 week post-AA treatment). Eyes were enucleated at 21 weeks and tumor sections were analyzed for hypoxia, angiogenesis, and tumor burden. Results: Eyes treated with 2-DG 1 day post-AA injection showed a 23% (P = 0.03) reduction in tumor burden compared with 2-DG alone and a 61% (P < 0.001) reduction compared with saline-treated eyes. Eyes treated with 2-DG 1 week post-AA injection showed no significant decrease in tumor burden compared with 2-DG alone (P = 0.21) and a 56% (P < 0.001) decrease in comparison with saline-treated eyes. 2-DG significantly reduced the total density of new blood vessels in tumors by 44% compared to saline controls (P < 0.001), but did not affect the density of mature vasculature. Conclusions: Combination therapy with angiogenic and glycolytic inhibitors significantly enhanced tumor control. Synergistic effects were shown to be dependent on the temporal course of treatment, emphasizing optimal timing. 2-DG was shown to reduce the density of neovessels, demonstrating an antiangiogenic effect in vivo. As a result, angiogenic and glycolytic inhibitors may have significant potential as alternative therapies for treating children with retinoblastoma.

Original languageEnglish (US)
Pages (from-to)129-137
Number of pages9
JournalClinical Ophthalmology
Volume5
Issue number1
StatePublished - Feb 7 2011

Keywords

  • Adjuvant therapies
  • Angiogenic inhibitors
  • Glycolytic inhibitors
  • Retinoblastoma

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Novel retinoblastoma treatment avoids chemotherapy: The effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH<sub>BETA</sub>T<sub>AG</sub> retinoblastoma tumors'. Together they form a unique fingerprint.

  • Cite this